{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:20Z","timestamp":1781190860063,"version":"3.54.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ad.2025.104539","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:58:27Z","timestamp":1765209507000},"page":"104539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RF \u2013 Tildrakizumab 200mg. Is Double Dosing Really a Window of Opportunity?"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-2229","authenticated-orcid":false,"given":"C.","family":"Llamas-Segura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cebolla-Verdugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104539_bib0030","unstructured":"Ficha t\u00e9cnica de Ilumetri\u00ae (tildrakizumab). Available from: https:\/\/www.ema.europa.eu\/documents\/productinformation\/ilumetri-epar-product-information_es.pdf. [Accessed October 2024]."},{"key":"10.1016\/j.ad.2025.104539_bib0035","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s13555-022-00789-9","article-title":"High tolerability, favorable safety, and subjects\u2019 preference for a single 200mg\/2mL tildrakizumab injection: a phase I, open-label, randomized crossover trial in healthy volunteers","volume":"12","author":"Kokolakis","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104539_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2350760","article-title":"Comparative effectiveness of tildrakizumab 200mg versus tildrakizumab 100mg in psoriatic patients with high disease burden or above 90kg of body weight: a 16-week multicenter retrospective study \u2013 IL PSO (Italian landscape psoriasis)","volume":"35","author":"Gargiulo","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.104539_bib0045","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.3390\/jcm13175240","article-title":"Uncovering the differences: how DLQI and WHO-5 scores vary in moderate-to-severe psoriasis patients treated with tildrakizumab 100mg vs. 200mg?","volume":"13","author":"Trovato","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2025.104539_bib0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ad.2020.11.017","article-title":"Burden of psoriasis in Catalonia: epidemiology, associated comorbidities, health care utilization, and sick leave","volume":"112","author":"Puig","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:42:56Z","timestamp":1781188976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025008154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001731025008154"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104539","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RF \u2013 Tildrakizumab 200mg. Is Double Dosing Really a Window of Opportunity?","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104539"}}